Doxorubicin-loaded cyclodextrin-tamoxifen citrate inclusion complex drug delivery system and use thereof

By using a synergistic system of hydroxypropyl-β-cyclodextrin with propylene glycol alginate and leucine, the solubility and stability issues of tamoxifen citrate have been resolved, achieving highly efficient drug inclusion and stability, making it a suitable formulation for breast cancer treatment.

CN121177516BActive Publication Date: 2026-07-03XINYI CITY PEOPLES HOSPITAL
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
XINYI CITY PEOPLES HOSPITAL
Filing Date
2025-11-12
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Tamoxifen citrate has low solubility and dissolution rate, and poor chemical stability. Existing drug delivery systems cannot achieve efficient and stable inclusion, resulting in high drug leakage rate and failing to meet clinical requirements for high bioavailability and high stability of the formulation.

Method used

Hydroxypropyl-β-cyclodextrin was used as the inclusion material, combined with a synergistic system of propylene glycol alginate and leucine. By precisely controlling the temperature and pH value, a cyclodextrin-tamoxifen citrate inclusion complex was prepared to form a stable inclusion structure, improve the encapsulation efficiency and reduce the leakage rate.

Benefits of technology

It significantly improves the inclusion rate, reduces drug leakage rate, and ensures drug stability during storage. It is suitable for preparing tablets, granules, and oral solutions, providing a more stable and efficient option for breast cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121177516B_ABST
    Figure CN121177516B_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of antitumor drugs, and relates to a cyclodextrin-tamoxifen citrate inclusion compound drug delivery system and application thereof. The application aims to solve the problems of low solubility and poor stability of tamoxifen citrate and poor material adaptability in the existing cyclodextrin inclusion technology. The cyclodextrin-tamoxifen citrate inclusion compound drug delivery system contains tamoxifen citrate, cyclodextrin, a buffer solution, propylene glycol alginate and leucine. The system can be used to prepare tablets, granules and other preparations for antitumor drug preparation. The application significantly improves the drug inclusion rate and stability by adapting the inclusion material and the auxiliary materials to work together and combining the temperature control process. The process is simple and controllable, suitable for industrialization, and has clinical application value.
Need to check novelty before this filing date? Find Prior Art